The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta ...

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic ...

The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

Hair loss can be a frustrating experience, whether it’s thinning, receding, or shedding in patches. It affects millions of ...

Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA).

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

If you have lupus, you and your doctors can work together to find the right treatment plan for you. Living with lupus can be hard, but there’s a lot you can do to manage your symptoms and make your ...

The current plan is that after ... and be randomly allocated to treatment with either rituximab or placebo. The primary endpoint of FIRST will be cumulative time spent in Lupus Low Disease ...

Some patients with lupus who possess specific antibodies are at a higher risk of thrombotic events such as a blood clot, stroke or heart attack, a new study led by Johns Hopkins ...

Citizens' groups converged on the Capitol Tuesday to demand that Gov. Evers fight harder for progressive budget priorities ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

In March 2025, Nkarta announced a restructuring plan, including a reduction in force ... including NKX019 for the treatment of autoimmune diseases, such as lupus, primary membranous nephropathy, ...